Glycogen Synthase Kinase 3 Inhibitors
| Cat. No. | Product Name / Activity |
|---|---|
| 4083 | 3F8 |
| Potent and selective GSK-3β inhibitor | |
| 4431 | A 1070722 |
| Highly potent, selective GSK-3 inhibitor | |
| 6400 | Alsterpaullone |
| GSK-3β inhibitor; also inhibits CDK1/2 and Lck | |
| 3966 | AR-A 014418 |
| Selective GSK-3 inhibitor | |
| 7650 | AZD 2858 |
| Highly potent GSK-3 inhibitor; inhibits tau phosphorylation | |
| 3194 | BIO |
| Potent GSK-3 inhibitor; also inhibits cdks | |
| 3874 | BIO-acetoxime |
| Selective GSK-3α/β inhibitor | |
| 6695 | CHIR 98014 |
| Highly potent and selective GSK-3 inhibitor | |
| 4423 | CHIR 99021 |
| Highly selective GSK-3 inhibitor; acts as Wnt activator | |
| 4953 | CHIR 99021 trihydrochloride |
| Hydrochloride salt of CHIR 99021 (Cat. No. 4423); selective GSK-3 inhibitor | |
| 1813 | Indirubin-3'-oxime |
| GSK-3β inhibitor; also inhibits cdks and other protein kinases | |
| 1398 | Kenpaullone |
| GSK-3β inhibitor; also inhibits cdks | |
| 4740 | Lithium carbonate |
| Mood stabilizer; inhibits GSK-3 in vivo | |
| 3873 | MeBIO |
| Inactive analog of BIO (Cat. No. 3194) | |
| 1616 | SB 216763 |
| Potent, selective GSK-3 inhibitor | |
| 1617 | SB 415286 |
| Potent, selective GSK-3 inhibitor | |
| 4353 | TC-G 24 |
| Potent and selective GSK-3β inhibitor | |
| 3869 | TCS 2002 |
| Potent GSK-3β inhibitor | |
| 4221 | TCS 21311 |
| GSK-3β inhibitor. Also inhibits PKC and JAK3 | |
| 6092 | TDZD 8 |
| Selective non-ATP competitive inhibitor of GSK 3β | |
| 7405 | TWS 119 |
| Potent GSK3 inhibitor; induces neuronal and CD8(+) T cell differentiation |
Our Cancer Research Guide highlights over 750 products for cancer research.
Request copyRequest PDF
Our Kinase listing highlights over 400 products for kinase research.
Request copyRequest PDF
Our guide highlights the use of small molecules in stem cell research and cell therapy and lists relevant products.
Request copyRequest PDF
Our Stem Cells review gives an overview of the use of small molecules in the control of stem cell growth & differentiation and somatic cell reprogramming.
Request copyRequest PDFWritten by Alan Palmer
Our Alzheimer's disease poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease.
Request copyDownload PDFWritten by Justin M. Saunders and Javier González-Maeso
Our Schizophrenia poster highlights the targets and pathways representing the most promising strategies to pursue for novel drug development.
Request copyDownload PDF
Written by Rebecca Quelch and Stefan Przyborski, this poster summarizes the isolation of pluripotent stem cells, their maintenance in culture, differentiation, and potential uses.
Request copyDownload PDF